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Abstract: Many dyspneic patients who undergo computerized tomographic pulmonary angiography (CTPA)
for presumed acute pulmonary embolism (PE) have no identified cause for their dyspnea yet have persistent
symptoms, leading to more CTPA scanning. Right ventricular (RV) dysfunction or overload can signal
treatable causes of dyspnea. We report the rate of isolated RV dysfunction or overload after negative CTPA
and derive a clinical decision rule (CDR). We performed secondary analysis of a multicenter study of
diagnostic accuracy for PE. Inclusion required persistent dyspnea and no PE. Echocardiography was ordered
at clinician discretion. A characterization of isolated RV dysfunction or overload required normal left ventric-
ular function and RV hypokinesis, or estimated RV systolic pressure of at least 40 mmHg. The CDR was
derived from bivariate analysis of 97 candidate variables, followed by multivariate logistic regression. Of
647 patients, 431 had no PE and persistent dyspnea, and 184 (43%) of these 431 had echocardiography
ordered. Of these, 64 patients (35% [95% confidence interval (CI): 28%–42%]) had isolated RV dysfunction
or overload, and these patients were significantly more likely to have a repeat CTPA within 90 days (P = .02,
χ2 test). From univariate analysis, 4 variables predicted isolated RV dysfunction: complete right bundle
branch block, normal CTPA scan, active malignancy, and CTPA with infiltrate, the last negatively. Logistic
regression found only normal CTPA scanning significant. The final rule (persistent dyspnea + normal
CTPA scan) had a positive predictive value of 53% (95% CI: 37%–69%). We conclude that a simple CDR
consisting of persistent dyspnea plus a normal CTPA scan predicts a high probability of isolated RV dys-
function or overload on echocardiography.
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tomography, spiral computed.
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In the past decade, multidetector-row computerized tomo-
graphic pulmonary angiography (CTPA) has become the
imaging mainstay in the diagnosis and exclusion of acute
pulmonary embolism (PE). CTPA can also disclose clini-
cally important alternative diagnoses, most often pulmonary
infiltrates suggestive of pneumonia.1,2 However, CTPA is
not without harm and has been known to cause adverse
effects, including radiation exposure, contrast nephropathy,
and false positive diagnoses.3-10 Despite these risks, the
rate of CTPA recidivism has increased in recent years. For
example, in one study, almost 40% of patients who had
CTPA in the years 2000–2001 underwent a second CTPA
scan that was negative for PE within the next few years.11
Approximately 70% of patients who undergo CTPA
scanning have dyspnea as a chief complaint, and many of
these patients continue to have dyspnea despite normal
imaging studies and a negative emergency department
(ED) evaluation.12 Persistent dyspnea is a major reason
that many patients return to an ED and often receive a
repeat CTPA scan.11 These data suggest that pathologies
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other than PE are responsible for persistent/recurrent
symptoms and recurrent use of health care resources such
as CTPA.
Pulmonary hypertension (PH) is a proliferative and
sometimes obstructive vasculopathy defined by a mean
pulmonary arterial pressure higher than 25 mmHg with a
normal pulmonary arterial capillary wedge pressure. If left
untreated, PH can cause right ventricular (RV) failure and
death. PH has multiple etiologies, including idiopathic, he-
reditary, connective-tissue disease, HIV, congenital heart
disease, and portal hypertension (collectively termed “pul-
monary arterial hypertension” [PAH]), or it may occur as a
secondary complication of treatable diseases, including left
heart disease, chronic lung disease, and sleep-disordered
breathing.13-17 However, although PH has major implica-
tions on morbidity and mortality, recent studies suggest
that it is frequently overlooked and underrecognized.18,19
Early diagnosis and treatment improve outcomes. Since RV
function determines functional status, exercise capacity,
and outcomes in PH, and since RV dysfunction is com-
monly observed in PH patients, we hypothesized that a
substantial portion of patients with persistent dyspnea, de-
spite negative CTPA for PE, have unrecognized RV dys-
function or overload on echocardiography that contributes
to persistent symptoms and CTPA recidivism.20,21 The iden-
tification of such patients would allow for the diagnosis and
treatment of correctable etiologies (e.g., PAH, chronic heart
or lung disease, chronic sleep-disordered breathing). In
chronic obstructive pulmonary disease (COPD), RV dys-
functionmay precede the development of frank PH.22
One prior study reported on a subset of ED patients
with dyspnea in the PRIDE study who underwent echo-
cardiography as part of standard care.23 In this sample of
134 patients, the authors found that 20% had RV hypo-
kinesis and 30% had moderate or severe tricuspid regur-
gitation. However, to our knowledge, no prior literature
has examined the frequency of RV dysfunction or over-
load after negative CTPA. We therefore performed this
study on patients with negative CTPA scanning and per-
sistent dyspnea to derive a simple clinical decision rule
(CDR) to predict a high probability of RV dysfunction or
overload on echocardiography and to test whether RV dys-
function was associated with CTPA recidivism.
METHODS
Study design
This was a secondary analysis of a 4-center prospective,
noninterventional study of diagnostic accuracy. The de-
tails of the methods have been published previously.12 For
the main analysis, we included only patients who had a
CTPA negative for PE, had persistent dyspnea, and had
transthoracic echocardiography performed within 1 week
of enrollment.
Study setting and population
Patients undergoing CTPA scanning for suspected PE were
prospectively enrolled at 4 academic medical centers in the
United States: Carolinas Medical Center, Charlotte, North
Carolina; Northwestern Memorial Hospital, Chicago, Illi-
nois; Wake Forest University Baptist Hospital, Winston-
Salem, North Carolina; and Baystate Hospital, Springfield,
Massachusetts. All patients provided written informed con-
sent. The study was approved by the institutional review
boards of the 4 participating centers. The study protocol
was registered on ClinicalTrials.gov before enrollment (iden-
tifier NCT00368836).
Experienced research coordinators initiated the
screening process with discovery of an order entry for a
CTPA scan from anywhere within the hospital, 6 days
per week, 12 hours per day. Based on preliminary work
that showed that CTPA scans were ordered in equal pro-
portions for inpatients and ED patients, the screening
process was designed to produce equal proportions of
enrolled inpatients and outpatients.24 Inclusion criteria
required that patients had 1 of 15 signs or symptoms of
PE and 1 of 21 known risk factors for PE (Table 1) and
had a CTPA scan ordered.6 Patients were excluded if
they were unlikely to provide follow-up (e.g., imprison-
ment, homelessness, no telephone, history of noncompli-
ance) or if they were hemodynamically unstable or in-
tubated, had prior fibrinolytic treatment within 48 hours,
had PE diagnosed within the last 6 months and were cur-
rently receiving systemic anticoagulation, had known ac-
tive tuberculosis, or refused to give consent. Patients were
enrolled within 24 hours of CTPA imaging.
Study protocol
CTPA images were obtained at each site as part of stan-
dard care with 64-channel multidetector equipment, capa-
ble of ≤2.5-mm collimation.6 Intravenous contrast was
given to all patients according to local protocol; a computer-
controlled mechanized timing injector was used in all
cases. Images were obtained with energy, pitch, and rota-
tion settings as required for the patient’s body habitus.
Contiguous 1.25-mm-thick images were routinely re-
constructed at mediastinal (width: 400 Hounsfield units
[HU]; center: 0 HU) and lung (width: 1,600 HU; center:
600 HU) window settings. All patients had reconstruc-
tions that included transverse, coronal, and sagittal
views. Images were converted to a digital file with a Dig-
172 | RV dysfunction after negative CTPA Kline et al.
ital Imaging and Communications in Medicine format,
devoid of any annotations or protected health informa-
tion, and were transferred to an independent reference
reading (IRR) laboratory (Medical Metrics, Houston). Ra-
diologists read the examinations on a standard picture-
archiving and communication workstation and were free
to modify their window settings as needed.
Clinical, breath, and blood data collection. To mini-
mize missing or biased data and to simulate the knowl-
edge held by decider clinicians, clinical data were obtained
in real time at the bedside, as opposed to chart review,
including all data in Tables 1 and 2. Each data field had
an explicit definition, and coordinators were trained by the
principal investigator (JK) according to an explicit set of
Table 1. Predictor variables: demographics and symptoms and comorbidities
Echo done
(n = 184)
Echo not done
(n = 247)
Echo with
isolated RV
dysfunction
or overload
(n = 64)
Echowith
normal RV and
LV function
(n = 75)
n % n % P n % n % P
Inpatient, acute care 93 51 86 35 .001 24 38 38 51 .120
Inpatient,
rehabilitation 2 1 3 1 .903 2 3 0 0 .123
ED patient 84 46 150 61 .002 36 56 34 45 .199
Male 77 42 83 34 .080 20 31 33 44 .123
Hispanic 10 5 13 5 .938 2 3 2 3 .872
Black 62 34 80 32 .775 20 31 23 31 .941
Native American 1 1 0 0 .246 0 0 1 1 .354
White 118 64 161 65 .821 42 66 50 67 .897
Asian 1 1 0 0 .246 0 0 1 1 .354
Alternate diagnosis
more likely than PE 96 52 124 50 .685 31 48 39 52 .675
Chest pain reproduced
on palpation 29 16 49 20 .277 10 16 13 17 .787
Pleuritic chest pain 47 26 83 34 .071 17 27 19 25 .869
Substernal chest pain 29 16 60 24 .030 10 16 15 20 .503
Angina-like pain 4 2 8 3 .506 2 3 2 3 .872
Unilateral arm or leg
swelling 33 18 35 14 .289 12 19 15 20 .853
New onset dyspnea 129 70 174 70 .940 44 69 54 72 .675
Dyspnea worse than
usual/persistent 31 17 50 20 .372 8 13 11 15 .711
Syncope 6 3 4 2 .263 3 5 3 4 .842
Chest pain 67 36 97 39 .545 24 38 29 39 .888
Confusion 5 3 9 4 .592 1 2 3 4 .392
Upper abdominal pain 9 5 24 10 .062 4 6 5 7 .921
Upper back pain 17 9 30 12 .338 4 6 9 12 .246
Hemoptysis 6 3 6 2 .604 2 3 2 3 .872
Dizziness 30 16 51 21 .254 10 16 14 19 .636
Cough 69 38 117 47 .041 25 39 25 33 .483
Limb swelling 15 8 12 5 .163 5 8 7 9 .750
Note: Echo: echocardiography; ED: emergency department; LV: left ventricular; PE: pulmonary embolism; RV: right ventricular.
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Table 2. Predictor variables: comorbidities
Echo done
(n = 184)
Echo not done
(n = 247)
Echo with
isolated RV
dysfunction
or overload
(n = 64)
Echo with
normalRV and
LV function
(n = 75)
n % n % P n % n % P
No prior lung disease 133 72 158 64 .068 47 73 49 65 .303
COPD 20 11 34 14 .369 8 13 11 15 .711
Asthma 32 17 51 21 .396 11 17 14 19 .821
Other nonmalignant
lung disease 12 7 18 7 .757 3 5 6 8 .429
Never smoked 118 64 141 57 .140 40 63 47 63 .984
Past smoker, stopped 31 17 54 22 .196 13 20 14 19 .807
Smoker, ≤10
cigarettes/day 21 11 32 13 .630 6 9 10 13 .466
Smoker, >10
cigarettes/day 19 10 25 10 .945 6 9 7 9 .993
Malignancy, prior
history 14 8 18 7 .900 5 8 6 8 .967
Malignancy, under
treatment 19 10 31 13 .476 11 17 5 7 .053*
Kidney dialysis 3 2 4 2 .993 0 0 2 3 .188
Warfarin in past 7 days 22 12 26 11 .641 5 8 8 11 .565
Recent surgery 17 9 47 19 .005 6 9 8 11 .801
Bed rest or
hospitalization, >72 h 25 14 41 17 .390 10 16 8 11 .385
Current trauma 2 1 3 1 .903 0 0 1 1 .354
Recent trauma 0 0 4 2 .083 0 0 0 0 NA
Thrombophilia 1 1 5 2 .194 0 0 0 0 NA
Estrogen replacement
therapy 10 5 25 10 .078 3 5 5 7 .618
Pregnancy or post
partum 4 2 3 1 .436 3 5 1 1 .238
Immobility>48 h in
past 3 days 3 2 6 2 .566 0 0 2 3 .188
Paralysis of one or
more limbs 2 1 2 1 .767 1 2 0 0 .277
Stroke 4 2 1 0 .090 1 2 2 3 .655
Left heart failure 22 12 21 9 .237 6 9 6 8 .774
Intravenous drug use 1 1 1 0 .834 1 2 0 0 .277
DVT without PE 3 2 7 3 .412 0 0 2 3 .188
Active connective-tissue
disease 10 5 8 3 .260 2 3 4 5 .523
Focal infection 17 9 25 10 .760 8 13 4 5 .134
New onset renal failure 3 2 3 1 .716 0 0 2 3 .188
Neuromuscular disease 1 1 0 0 .246 0 0 1 1 .354
BMI > 36 42 23 65 26 .407 18 28 17 23 .460
Note: BMI: body mass index; COPD: chronic obstructive pulmonary disease; DVT: deep venous thrombosis; Echo: echocardiog-
raphy; LV: left ventricular; NA: not applicable; PE: pulmonary embolism; RV: right ventricular.
* P < .1.
standard operating procedures on how to collect them. Vi-
tal signs recorded were those closest in time to when the
patient was enrolled, and all pulse oximetry readings were
obtained with the patient breathing room air. Blood sam-
ples were drawn by qualified phlebotomists within 12 hours
of CTPA scanning, and the D-dimer assay and fibrinogen
concentrations were analyzed on instruments cleared by
the US Food and Drug Administration.12 For collection of
breath data, including end-tidal CO2 and O2, and respi-
ratory mechanical values (tidal volume, minute ventila-
tion, inspiratory and expiratory flow rates and times, air-
way dead space volume, and oxygen and CO2 volume),
patients breathed room air, wore a nose clip, and breathed
into a duckbill mouthpiece for 1–2 minutes, as previously
described.24
CTPA interpretation. Interpretations by the IRR labora-
tory (Medical Metrics), as well as the site interpretation,
were integrated into this analysis. At the site hospitals,
images were interpreted by board-certified hospital radiol-
ogists who had completed a fellowship in emergency ra-
diology or body imaging. Later, at the IRR laboratory,
images that were stripped of protected health information
and any added comments or markings were interpreted
by 1 of 2 board-certified radiologists who had completed
fellowship training in body imaging. The IRR radiologists
interpreted images as “no PE,” “positive for acute PE”, or
“positive for chronic PE.” Chronic PE was characterized
by 3 criteria: indistinct or fuzzy margins of the filling
defect, adherence of clot to the vessel wall, and a webbed
or “plexiform” appearance of the filling defect.25,26 “Posi-
tive for other finding” was further graded, including a
specific code for pulmonary infiltrate suggestive of pneu-
monia (which had to be read both at the site and by the
IRR) or parenchymal lung disease. Parenchymal lung dis-
ease was considered present if the IRR indicated findings
of emphysema, fibrosis, scarring, or diffuse ground-glass
appearance. Radiologists were not asked to systemically
grade the severity of these findings. They could, however,
make a comment about the finding, and many used the
words “mild,” “moderate,” or “severe.” All CTPA scans
were also evaluated for evidence of RV dilation, defined as
a ratio of the RV diameter to the left ventricular (LV) di-
ameter greater than 0.9 in transverse plane.27,28 The IRR
radiologist also dichotomously recorded a field designated
as “signs of pulmonary hypertension,” based on findings of
enlarged diameter (RV/LV diameter ratio >0.9) with or with-
out contrast reflux into the vena cava, dilated central pulmo-
nary arteries (e.g., diameter of main pulmonary artery
greater than that of ascending aorta), tortuous pulmonary
arteries, vascular pruning, and/or a mosaic perfusion pat-
tern, defined as sharply demarcated regions of variable
attenuation without evidence of destruction or displace-
ment of pulmonary vessels.29 All parameters were weighed
equally, and radiologists were allowed autonomy to put
these findings together in making a dichotomous assess-
ment. A normal CTPA scan was defined as having no sig-
nificant pathological finding. Interpretations of CTPAs at
each site were performed as part of standard care, and
the final, written interpretation entered into the medical
record was abstracted with a standardized approach to de-
termine the site reading.
Echocardiography. Transthoracic echocardiograms were
performed within 7 days after CTPA scanning at the dis-
cretion of the clinical care team. All echocardiograms were
performed in IAC echocardiography-approved laboratories,
using contemporaneous equipment, and were interpreted
by board-certified cardiologists with specialty training in
echocardiography. We included only results of echocardio-
grams that had adequate acoustic imaging to evaluate RV
morphology and function. We abstracted data from the
standard echocardiographic clinical report form. RV dys-
function or overload was defined as present with any one
of the following: cardiologist qualitative interpretation of
RV hypokinesis, dilation (defined as an end-diastolic diam-
eter >35 mm in the apical 4-chamber view), or evidence of
PH (peak tricuspid regurgitant jet velocity >2.7 m/s, ob-
tained by continuous-wave spectral sampling from reliable
waves).30 Normal LV function required an ejection fraction
greater than 45% and no evidence of diastolic dysfunction.
Clinical follow-up. All patients had telephone follow-up
at 90 days. A scripted query was used, and a specific data
collection template was designed to discover interval ad-
verse events; diagnostic testing, including CTPA scan-
ning with the results; and any change in treatment status.
Data analysis
The primary patient sample consisted of those with per-
sistent dyspnea and no PE on CTPA. Persistent dyspnea
was defined as the patient’s statement that he or she had
the sensation of shortness of breath while breathing room
air at rest.
It could be expected that clinicians selected patients
with more severe symptoms for echocardiography; there-
fore, the first analysis compares frequency and parametric
clinical variables with a χ2 test and an unpaired t test,
respectively, between patients with and without echocardi-
ography. Specifically, we compared the 97 clinical vari-
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ables in Tables 1–4. To create the prediction rule, all can-
didate predictor variables were included and screened
with univariate analysis that used a χ2 test for frequency
data and an unpaired t test for parametric data. Dichoto-
mous variables with P < .1 were entered into multivariate
logistic regression analysis. Parametric values with P < .1
were subjected to receiver operating characteristic (ROC)
analysis to determine whether they had significant pre-
dictive value (i.e., lower limit of 95% confidence interval
[CI] above 0.5). Logistic model fit was assessed by P val-
ues from the Pearson’s goodness-of-fit χ2, the Hosmer-
Lemeshow test, the pseudo-R2 (McFadden), and the area
under the ROC curve in the derivation data set (C statis-
tic).31,32
RESULTS
Characteristics of the study population
and prevalence of RV dysfunction
Patients were enrolled from January 30, 2007, to April 27,
2008. Figure 1 shows a flow diagram of patients, starting
with subjects screened for inclusion and ending with
repeated CTPA instances. Six hundred seventy-eight pa-
tients signed a consent form and underwent CTPA, and
647 had complete data, including a CTPA and clinical,
blood, and breath sample data. The criterion standard for
any filling defect consistent with PE was found in 120 of
the 647 patients (18% [95% CI: 15%–22%]). Ninety-six
patients did not have persistent dyspnea, leaving 431 pa-
tients with persistent dyspnea. As part of usual care, clini-
cians ordered transthoracic echocardiography that yielded
adequate acoustic images for 186 of these 431 patients
(42%), with 2 having images inadequate to assess RV
function, leaving 247 who did not undergo echocardiogra-
phy. Of the 184 patients with usable echocardiography,
64 (35% [95% CI: 28%–42%]) had isolated RV dysfunc-
tion or overload, 45 (24%) had LV dysfunction, and 75
(41%) had normal RV and LV function (Fig. 1). Of the
64 patients with an abnormal RV on echo, 20 had RV
dilation or hypokinesis, together with an RV systolic pres-
sure higher than 35 mmHg; 24 had only dilation or
hypokinesis; and 20 had RV systolic pressure higher than
35 mmHg with normal RV size and contraction. Patients
with LV dysfunction were not included in the analysis.
On follow-up, 54 of the 647 patients (8%) had a repeat
CTPA for recurrent dyspnea.
Tables 1–4 compare predictor variables between patients
with (n = 184) and without (n = 247) echocardiography.
These tables then compare patients who had echocardiogra-
phy between those with isolated RV dysfunction (n = 64)
and those with normal RV and LV function (n = 75). Ta-
ble 1 compares demographic data and symptoms, Table 2
compares comorbid conditions, Table 3 compares mea-
sured continuous variables (e.g., vital signs and respiratory
data), and Table 4 compares bivariate results (e.g., CTPA
and electrocardiographic results). Of note, the prevalence
of parenchymal lung disease on CTPA was the same (23%)
in the group that had echocardiography and in the group
that did not, suggesting that this finding did not drive the
decision to order or not order an echocardiogram.
Differences between patients with
and without echocardiography
Comparisons of patients with and without echocardiogra-
phy in Tables 1–4 were performed with a χ2 or unpaired
t test, yielding P < .05 for age, inspiratory and expiratory
times, cough, recent surgery, and inpatient status. In par-
ticular, patients who underwent echocardiography were
more likely to be inpatients or ED patients, were less
likely to have substernal chest pain, pleuritic chest pain,
or cough, and were less likely to have had recent sur-
gery. Furthermore, they were likely to be older and to
have a lower Borg score. They were less likely to have an
S1Q3T3 pattern on electrocardiogram, but more likely to
have T wave inversions.
Parameters associated with RV dysfunction
In the group undergoing echocardiography (n = 184), 64
(35%) patients exhibited signs of RV dysfunction or over-
load (Fig. 1). Seventy-five (41%) patients had a normal
echocardiogram. Forty-five (24%) patients exhibited iso-
lated LV dysfunction; these patients were not included in
the analysis. The probability of isolated RV dysfunction or
overload on echocardiography was higher in ED patients
(36/86, 42%) than in inpatients/rehabilitation patients (26/
98, 27% [95% CI for difference of 15%: 16%–29%], P = .02,
exact binomial test). Because radiologists found RV dilation
(defined as RV/LV diameter ratio > 0.9) on CTPA in only 7
patients, 4 of whom underwent echocardiography, this vari-
able was not analyzed.
To select candidate variables for entry into multivariate
regression analysis, we compared data between the pa-
tients with isolated RV dysfunction and the patients with
normal echocardiograms. Analysis found that the mean
values of the parametric variables age and fibrinogen were
elevated with isolated RV dysfunction. However, neither
value had a significant area under the ROC curve and
were subsequently discarded. Dichotomous variables with
P < .1 positively associated with isolated RV dysfunction
included complete right bundle branch block, normal in-
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dex CTPA scan, and malignancy under treatment. CTPA
with infiltrate had a negative association.
Outcome data
Table 5 compares outcome data in a fashion similar to
that of the previous tables. Patients with isolated RV dys-
function were more likely to be newly diagnosed with
COPD or to have a repeat CTPA scan within 90 days.
Interestingly, none of the 36 patients in Table 5 with a
repeat CTPA scan had a new, acute pathogenic process
discovered that was not present on the index CTPA scan.
The 4 predictor variables retained after univariate and
ROC analysis (complete right bundle branch block, nor-
mal index CTPA scan, malignancy under treatment, and
CTPA with infiltrate) were entered into a logistic regres-
sion analysis. Table 6 shows the equation coefficients and
the corresponding P values for these variables. The model
had good fit, demonstrated by a Pearson’s goodness-of-fit
χ2 result of P = .52, a McFadden pseudo-R2 of 0.92, and a
Hosmer-Lomeshow test result of P = .95. This analysis
showed that only one variable, normal index CTPA scan,
had significance. Thus, we constructed a final rule con-
sisting of persistent dyspnea plus a normal CTPA scan as
the CDR to predict a high probability of isolated RV dys-
function on echocardiography. This rule was positive in
41 patients who underwent echocardiography, of whom
22 (53%) had isolated RV dysfunction (positive predic-
tive value: 53% [95% CI: 37%–69%]). Five of the 22 rule-
positive (CDR+) patients had a repeat CTPA scan within
90 days.
DISCUSSION
We found that 64 of 184 (35% [95% CI: 28%–42%]) pa-
tients who had persistent dyspnea after CTPA and a clini-
cal picture that caused clinicians to order echocardiography
had isolated RV dysfunction or overload. Hypothetically,
had echocardiography been ordered for all 431 patients
with dyspnea after CTPA and all other patients had a nor-
mal echocardiogram, the prevalence of isolated RV dys-
function or overload would still have been 64 of 431, or
15% (95% CI: 12%–18%). However, it is likely that the per-
formance of echocardiographic studies in the patients who
did not undergo echocardiography would have revealed at
least a few additional cases of RV dysfunction, thus likely
increasing that number. Restricting the sample to patients
with dyspnea and a normal CTPA scan (i.e., CDR+) in-
creased the prevalence of RV dysfunction or overload to
53% (95% CI: 37%–69%). Had the derived CDR been ap-
plied to the entire 647-patient population, the rule would
have been positive and therefore suggests that 103 (16%) of
patients should have been referred for echocardiography.
Isolated RV dysfunction on echocardiography was de-
fined as a composite of RV hypokinesis and/or evidence
of pathological tricuspid regurgitation, and it excluded
patients with systolic or diastolic LV dysfunction. Our
35% prevalence of isolated RV dysfunction or overload
appears to lie within the 95% CI for RV dysfunction from
the PRIDE study (Chen et al.23), which found a 30%
(95% CI: 22%–39%) prevalence of moderate or severe tri-
cuspid regurgitation. The two studies cannot be directly
compared because our patients all had negative CTPA
scanning before echocardiography, and the study by Chen
et al.23 was not intended to discover the rate of isolated RV
dysfunction and therefore did not report this variable ex-
plicitly. In a large sample of Veterans Affairs patients (n =
10,471, 97% male) who underwent transthoracic echocar-
diography, Maron and colleagues18 found that 14% (95%
CI: 13.0%–14.4%) had estimated pulmonary artery systolic
pressures of at least 40 mmHg. However, this study in-
cluded any echocardiography that was not done to evaluate
a specific cardiovascular disease (e.g., cardiac tamponade).
The prevalence of isolated RV dysfunction in our sam-
ple was significantly higher in patients from the ED set-
ting (42% [95% CI 31%–52%]). This is important, because
at most hospitals, more than half of all CTPA scans are
ordered from the ED, and most show no significant pa-
thology.11,33 At present, no clinical guideline exists to sug-
gest a next step for the persistently dyspneic patient with
Figure 1. Flow diagram of patients enrolled and results of
testing. CTPA: computerized tomographic pulmonary angiog-
raphy; LV: left ventricular; PE: pulmonary embolism; RV: right
ventricular.
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Table 3. Predictor variables measured on day of enrollment (continuous data)
Echo done
(n = 184)
Echo not done
(n = 247)
Echo with
isolated RV
dysfunction
or overload
(n = 64)
Echo with
normal RV and
LV function
(n = 75)
Parameter Mean SD Mean SD P Mean SD Mean SD P
General findings and vital signsa
Age, years 57.2 15.2 52.2 15.7 .001 59.8 15.5 54.7 14.4 .044*
Heart rate, beats/min 83.9 19.4 85.9 17.5 .279 81.3 19.9 84.0 18.0 .395
Respiratory rate, breaths/min 19.6 3.4 19.6 5.9 .934 19.6 3.3 19.6 3.9 .955
Systolic blood pressure, mmHg 130.6 20.2 127.0 21.3 .081 131.6 20.1 131.0 21.2 .859
Diastolic blood pressure, mmHg 74.9 16.3 73.7 12.6 .398 75.4 19.2 73.7 14.8 .558
SaO2, % 97.0 2.4 97.3 2.5 .337 96.9 2.4 97.1 2.4 .778
Temperature, °F 97.9 1.1 98.1 1.1 .028 97.9 1.0 97.9 1.1 .780
BMI 31.1 9.2 31.1 8.8 .982 32.4 9.8 30.5 8.7 .241
Borg score 3.0 2.5 3.6 2.4 .030 3.2 2.6 2.9 2.4 .490
Test results
D-dimer, ng/mL 1,393 2,196 1,222 1,692 .362 1,248 2,243 1,204 1,116 .881
Fibrinogen, mg/dL 586 733 582 628 .944 777 1,091 462 398 .022*
Respiratory parametersb
Respiratory rate, breaths/min 18.1 6.5 17.0 6.2 .074 17.5 5.8 17.8 6.8 .801
Maximum breath temperature, °F 36.0 0.7 35.9 0.7 .084 36.0 0.6 36.1 0.7 .155
Minimum etO2, mmHg 102.6 8.3 103.5 8.3 .303 102.7 9.0 102.2 7.4 .758
Median etO2, mmHg 106.8 8.4 107.4 8.2 .396 106.5 8.5 106.2 7.8 .831
Maximum etCO2, mmHg 37.5 5.9 37.8 6.2 .541 37.6 5.4 38.0 5.4 .669
Median etCO2, mmHg 35.7 5.9 36.3 6.0 .353 36.1 5.3 36.3 5.4 .788
Minute VO2, mL 653 221 658 242 .800 659 213 627 233 .395
Minute VCO2, mL 497 168 513 194 .372 506 159 480 177 .366
Respiratory quotient 0.77 0.08 0.79 0.11 .058 0.77 0.09 0.77 0.09 .941
Inspiratory flow rate, L/min −51.9 20.9 −51.1 18.8 .680 −51 20.9 −52.5 22.8 .719
Expiratory flow rate, L/min 52.8 24.0 51.0 22.4 .416 51 23.8 52.3 23.9 .803
Tidal volume, median, mL 691 266 728 285 .169 703 266 695 298 .875
Airway dead space, mL 231 38 228 37 .334 233 42 228 37 .482
Total minute ventilation, mL 11,751 3,675 11,644 4,111 .779 11,612 3,716 11,429 3,376 .761
Alveolar minute ventilation, mL 7,620 2,824 7,806 3,286 .538 7,608 2,872 7,427 2,799 .707
Inspiratory time, median, s 1.53 0.55 1.65 0.63 .035 1.53 0.55 1.57 0.59 .723
Expiratory time, median, s 2.16 0.77 2.35 0.98 .031 2.23 0.79 2.20 0.76 .863
Note: BMI: body mass index; Echo: echocardiography; etO2: end-tidal oxygen; etCO2: end-tidal carbon dioxide; LV: left ventricu-
lar; RV: right ventricular; SaO2: saturation level of oxygen; VO2: volume of oxygen; VCO2: volume of carbon dioxide.
a Vital signs measured in emergency department triage.
b Measured with mouthpiece and noseclips in place (see “Methods”).
* P < .1.
no diagnosis after CTPA. Patients with isolated RV dys-
function or overload had a significantly higher rate of neg-
ative CTPA recidivism, suggesting continued symptoms
and unwise use of healthcare resources. This is in line
with data from the PAH literature that indicate that pa-
tients frequently are undiagnosed for 2 years or more,
after being subjected to myriad diagnostic tests, before
they are ultimately diagnosed with PAH.34,35 These find-
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Table 4. Predictor variables measured on day of enrollment (bivariate data)
Echo done
(n = 184)
Echonot done
(n=247)
Echo with
isolated RV
dysfunction
or overload
(n = 64)
Echo with
normal RV and
LV function
(n = 75)
Parameter n % n % P n % n % P
Elevated serum creatinine
(>1.5 mg/dL) 10 5 11 4 .762 3 5 4 5 .882
Elevated serum troponin I
(>99th percentile) 27 15 15 6 .080 6 9 5 7 .500
Index CTPA normal 41 22 62 24 .50 22 34 14 19 .035*
Index CTPA infiltratea 9 5 25 10 <.001 0 0 6 8 .021*
Index CTPA with signs of PHb 7 4 1 0 .01 4 6 1 1 .120
Index CTPA parenchymal
diseasea,c 42 23 66 23 .28 18 28 13 17 .120
Electrocardiogram findings
Normal sinus rhythm 141 77 175 71 .180 51 80 62 83 .653
Sinus tachycardia 36 20 47 19 .889 11 17 10 13 .527
Incomplete RBBB 8 4 7 3 .396 1 2 5 7 .140
Complete RBBB 8 4 9 4 .710 5 8 0 0 .014*
ST depression 2 1 4 2 .641 0 0 0 0 NA
S1Q3T3 3 2 13 5 .048 1 2 1 1 .910
T wave inversion > 1 mm in
V1–V4 8 4 3 1 .041 2 3 3 4 .782
Note: CTPA: computerized tomographic pulmonary angiography; Echo: echocardiography; LV: left ventricular; NA: not applica-
ble; PH: pulmonary hypertension; RBBB: right bundle branch block; RV: right ventricular.
a Subset of “other findings” described in “Methods”; infiltrate required agreement by the site and the independent reading
radiologist.
b At radiologist’s discretion, based on findings of enlarged right ventricle with or without contrast reflux into the vena cava,
dilated central pulmonary arteries, tortuous arteries, vascular pruning, and/or a mosaic perfusion pattern.
c Emphysema, fibrosis, scarring, ground-glass appearance.
* P < .1.
ings triggered a national early-diagnosis campaign for PH
(http://www.sometimesitsph.org).20,36 Our findings sug-
gest that the ED would be an important setting to be
included in such efforts. Data in Table 2 indicate that
patients with isolated RV dysfunction or overload seldom
had other severe associated comorbidities, such as COPD
or end-stage cancer. We believe that, taken together, the
data suggest that the isolated RV dysfunction or overload
had a causative role in persistent symptoms. These data
support a theoretical construct to develop an organized
clinical protocol that would include echocardiography as
an initial follow-up test for selected patients after negative
CTPA scanning, followed by referral to a specialty clinic
that can carry out a structured algorithm to evaluate for
treatable causes of PH and/or RV dysfunction.37
We therefore derived a CDR as an initial step. Using
the univariate-multivariate approach, the final rule con-
sisted of 2 independent criteria: a negative CTPA scan
and persistent dyspnea. More than half (53%) of the pa-
tients with echocardiography and a positive CDR had
isolated RV dysfunction. In a companion paper38 we
found that in a validation sample of persistently dys-
pneic ED patients with negative CTPA scanning and with
echocardiography, 33% (95% CI: 25%–42%) had isolated
RV dysfunction. Next steps will be to devise a clinical
pathway that refers CDR+ patients for transthoracic echo-
cardiography, followed by appropriate referral.37 Such a
structured diagnostic approach will likely allow for identi-
fying causes of RV dysfunction or overload and for initiat-
ing appropriate additional diagnostic and therapeutic mea-
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sures, with the ultimate goal of improving outcomes and
decreasing unnecessary use of healthcare resources.
Limitations
In this derivation, the final rule was restricted to patients
with a normal CTPA, which excluded patients with radio-
graphic evidence of chronic diseases, such as cardiomeg-
aly, emphysema, or scarring. In a secondary analysis, we
created a variable with a broader definition, named “CTPA
without acute process” (i.e., no PE, infiltrate, aortic dissec-
tion or aneurysm, pneumothorax, mediastinal mass, or
lung mass). Substitution of that variable instead of the
requirement for a normal CTPA in the CDR would have
led to a predictive value positive of 64/179, or 36% (95%
CI: 29%–43%). Other limitations to the work include our
inability to determine whether patients with our definition
of isolated RV dysfunction have treatable causes. For ex-
ample, the potential contribution of World Health Organi-
zation group 3 PH is difficult to assess, because radiolo-
gists were not asked to systematically grade the severity of
parenchymal abnormalities. However, most of our cases of
parenchymal scarring were mild. This does not change our
key message, however, that patients with persistent dysp-
nea and evidence of RV dysfunction need to undergo
Table 5. Outcomes based on echocardiography status
Echo done
(n = 184)
Echo not done
(n= 247)
Isolated RV
dysfunction
or overload
(n = 64)
Echo with
normal RV and
LV function
(n = 75)
Diagnosis/outcome n % n % P n % n % P
Sepsis 1 1 2 1 .74 0 0 0 0 NA
Deep venous thrombosis 1 1 3 1 .47 0 0 1 1 .35
Anxiety 2 1 2 1 .77 0 0 1 1 .35
Pneumonia 20 11 25 10 .80 8 13 5 7 .24
Coronary artery disease 4 2 2 1 .23 0 0 2 3 .19
Cardiomyopathy 2 1 1 0 .40 0 0 0 0 NA
Pericarditis 2 1 0 0 .10 0 0 2 3 .19
Rib fracture 0 0 1 0 .39 0 0 0 0 NA
Newly diagnosed COPD 7 4 4 2 .15 4 6 0 0 .03*
Heart failure 12 7 2 1 .00 3 5 1 1 .24
Pulmonary embolism 0 0 0 0 NA 0 0 0 0 NA
Chest pain, NOS 37 20 54 22 .66 0 0 0 0 NA
Pneumothorax 0 0 1 0 .39 0 0 0 0 NA
Asthma 1 1 5 2 .19 0 0 0 0 NA
Myocardial infarction 3 2 1 0 .19 0 0 0 0 NA
New solid tumor 1 1 2 1 .74 0 0 0 0 NA
New hematologic
malignancy 2 1 0 0 .10 0 0 0 0 NA
Pulmonary arterial
hypertension 0 0 0 0 NA 0 0 0 0 NA
Death 1 1 2 1 .74 0 0 0 0 NA
Other diagnosis 162 88 233 94 .08 40 63 55 73 .17
Any serious adverse event 36 20 68 28 .01 18 28 16 21 .35
No adverse events 109 59 167 68 .07 40 63 47 63 .98
Repeat CTPA within 90 days 22 12 14 6 .02 11 17 4 5 .03*
Note: All diagnoses were newly established. COPD: chronic obstructive pulmonary disease; CTPA: computerized tomographic
pulmonary angiography; Echo: echocardiography; NA: not applicable; NOS: not otherwise specified.
* P < .1.
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expert referral for identification of potentially treatable
causes of dyspnea. Second, our echocardiographic basis
for RV dysfunction includes heterogenous and controver-
sial criteria, and we recognize that tricuspid regurgitation–
derived indexes both over- and underestimate pulmonary
arterial pressures.39 We recognize that tricuspid regur-
gitation may occur with normal RV contractility, but in
the setting of PH, moderate-to-severe tricuspid regurgita-
tion worsens prognosis and is therefore considered to de-
fine RV dysfunction.40 We emphasize the intent to use
echocardiography as a screening criterion to move the pa-
tient on to a specialty clinic for more definitive diagnosis.
Third, RV dysfunction can be caused by many patholo-
gies.20,36 The current data do not allow for any conclu-
sions regarding the etiology of RV dysfunction. Fourth,
although this CDR is intended to align patients at high
risk for repeated CTPAs and repeated ED visits with treat-
ment to reduce symptoms, the proposed protocol could
unintentionally increase resource use and cost of care. Fi-
nally, the relationship between echocardiographic find-
ings of RV dysfunction or overload and persistent symp-
toms are only associative; these abnormalities may signify
pathology that drove patients back to the ED for repeat
testing, or the findings, if known by clinicians, may have
lowered their threshold to order a repeat CTPA. We do
not have specific data to understand the decision-making
process that clinicians used when they ordered repeat
CTPA scans.
Conclusions
A simple clinical decision rule, consisting of a normal com-
puterized tomographic pulmonary angiography scan and
persistent dyspnea, predicts a high probability of isolated
RV dysfunction or overload on echocardiography. Patients
with these features may benefit from referral for echocardi-
ography to evaluate for signs of pulmonary hypertension
and/or RV dysfunction, with subsequent referral for spe-
cialty evaluation for identification of potentially treatable
causes.
Source of Support: Nil.
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